Manila Times Business
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027 200 mg and 600 mg doses have been generally well-tolerated Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting further investigation WELLESLEY HILLS, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Race for quarters twice-to-beat advantage erupts
Just now
Lacson rejects claim Dela Rosa bounty meant to block impeachment vote
1h ago
Warm Sunday ahead for Metro Manila; Afternoon thunderstorms possible
1h ago
New Data 2026 On Rent, Buy, EMI or Second-Hand: What a Wardrobe Costs a Delhi Tenant Over an 11-Month Lease in 2026, as Rentomojo Prices a Mirrored Two-Door Cupboard at ₹312 a Month With Assembly, Repairs and the Next Move Included
1h ago